MetaVia (MTVA) Expected to Announce Quarterly Earnings on Thursday

Posted by Chris Copeland on Jul 30th, 2026

MetaVia (NASDAQ:MTVA – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect MetaVia to post earnings of ($0.85) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

MetaVia (NASDAQ:MTVA – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). On average, analysts expect MetaVia to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MetaVia Price Performance

MTVA opened at $1.44 on Thursday. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03. The stock has a market capitalization of $7.43 million, a price-to-earnings ratio of -0.28 and a beta of 0.97. The business has a fifty day moving average price of $1.97 and a 200 day moving average price of $1.94.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on MTVA shares. Wall Street Zen raised MetaVia to a “sell” rating in a research report on Saturday, June 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research report on Tuesday, July 21st. Finally, HC Wainwright restated a “buy” rating on shares of MetaVia in a research note on Friday, July 10th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.00.

Read Our Latest Analysis on MTVA

Institutional Inflows and Outflows

A hedge fund recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new stake in MetaVia Inc. (NASDAQ:MTVA – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.